File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: A 6-month study

TitleA comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: A 6-month study
Authors
Issue Date2006
PublisherLibrapharm Ltd.
Citation
Current Medical Research And Opinion, 2006, v. 22 n. 5, p. 929-937 How to Cite?
AbstractObjective: The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis. Methodology: A total of 104 patients (n = 47 teriparatide [20 μg/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand. Calcium (≥ 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study. Results: Teriparatide was associated with a 5.03 ± 4.77% increase in lumbar spine BMD (p < 0.0001, mean ± SD change from baseline), whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 ± 4.12%, p = 0.16). Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001). No statistically significant changes were observed for total hip or femoral neck BMD. Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, P = 0.24); osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03). Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively). There were no clinically relevant changes observed in laboratory parameters. Conclusions: Both treatments were similarly tolerated, however teriparatide was associated with greater increases in lumbar spine BMD and bone formation markers, demonstrating the unique mechanism of action and safety of this treatment for osteoporosis in these Asian women. © 2006 Librapharm Limited.
DescriptionThese data were presented in part at the Second Joint Meeting of the International Bone and Mineral Society (IBMS) and the European Society for Calcified Tissue (ECTS), 25-29 June 2005, Geneva, Switzerland
Persistent Identifierhttp://hdl.handle.net/10722/76638
ISSN
2015 Impact Factor: 2.643
2015 SCImago Journal Rankings: 0.896
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorPasion, EGen_HK
dc.contributor.authorSofiyan, Men_HK
dc.contributor.authorLau, EMCen_HK
dc.contributor.authorTay, BKen_HK
dc.contributor.authorLam, KSen_HK
dc.contributor.authorWilawan, Ken_HK
dc.contributor.authorOngphiphadhanakul, Ben_HK
dc.contributor.authorThiebaud, Den_HK
dc.date.accessioned2010-09-06T07:23:21Z-
dc.date.available2010-09-06T07:23:21Z-
dc.date.issued2006en_HK
dc.identifier.citationCurrent Medical Research And Opinion, 2006, v. 22 n. 5, p. 929-937en_HK
dc.identifier.issn0300-7995en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76638-
dc.descriptionThese data were presented in part at the Second Joint Meeting of the International Bone and Mineral Society (IBMS) and the European Society for Calcified Tissue (ECTS), 25-29 June 2005, Geneva, Switzerland-
dc.description.abstractObjective: The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis. Methodology: A total of 104 patients (n = 47 teriparatide [20 μg/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand. Calcium (≥ 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study. Results: Teriparatide was associated with a 5.03 ± 4.77% increase in lumbar spine BMD (p < 0.0001, mean ± SD change from baseline), whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 ± 4.12%, p = 0.16). Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001). No statistically significant changes were observed for total hip or femoral neck BMD. Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, P = 0.24); osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03). Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively). There were no clinically relevant changes observed in laboratory parameters. Conclusions: Both treatments were similarly tolerated, however teriparatide was associated with greater increases in lumbar spine BMD and bone formation markers, demonstrating the unique mechanism of action and safety of this treatment for osteoporosis in these Asian women. © 2006 Librapharm Limited.en_HK
dc.languageengen_HK
dc.publisherLibrapharm Ltd.en_HK
dc.relation.ispartofCurrent Medical Research and Opinionen_HK
dc.subject.meshAge Factorsen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAsia, Southeasternen_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshBone Density - drug effectsen_HK
dc.subject.meshBone Density Conservation Agents - pharmacology - therapeutic useen_HK
dc.subject.meshCalcitonin - pharmacology - therapeutic useen_HK
dc.subject.meshChinaen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFractures, Bone - etiology - prevention & controlen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOsteoporosis, Postmenopausal - drug therapy - physiopathologyen_HK
dc.subject.meshRisk Assessmenten_HK
dc.subject.meshRisk Factorsen_HK
dc.subject.meshTeriparatide - pharmacology - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleA comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: A 6-month studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0300-7995&volume=22&spage=929&epage=37&date=2006&atitle=A+comparison+of+teriparatide+and+calcitonin+therapy+in+postmenopausal+Asian+women+with+osteoporosis:+a+6-month+studyen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1185/030079906X104768en_HK
dc.identifier.pmid16709314-
dc.identifier.scopuseid_2-s2.0-33745036172en_HK
dc.identifier.hkuros118429en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745036172&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue5en_HK
dc.identifier.spage929en_HK
dc.identifier.epage937en_HK
dc.identifier.isiWOS:000238447700012-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridPasion, EG=6505876740en_HK
dc.identifier.scopusauthoridSofiyan, M=6503881187en_HK
dc.identifier.scopusauthoridLau, EMC=7103086055en_HK
dc.identifier.scopusauthoridTay, BK=7101924558en_HK
dc.identifier.scopusauthoridLam, KS=10042808900en_HK
dc.identifier.scopusauthoridWilawan, K=6506305665en_HK
dc.identifier.scopusauthoridOngphiphadhanakul, B=7004840966en_HK
dc.identifier.scopusauthoridThiebaud, D=7005184974en_HK
dc.identifier.citeulike625140-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats